Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology is viewed positively because the settlement with Nerviano removes a major overhang on onvansertib’s global rights, eliminates all outstanding litigation claims, and strengthens the company’s exclusivity and development position around its lead PLK1 inhibitor. The investment case is further supported by CRDF-004 data in first-line RAS-mutated metastatic colorectal cancer, where 30mg onvansertib plus FOLFIRI and bevacizumab produced a 72.2% ORR versus 42.1% for control, with median PFS not reached versus ~11 months, suggesting meaningful efficacy in a large underserved population. These clinical signals, combined with ongoing evaluation in other PLK1-driven cancers and a manageable safety profile, support the view that onvansertib could address treatment resistance and drive value as development advances.

Cardiff Oncology is facing a materially weaker outlook because its lead asset, onvansertib, carries only a 25% probability of launch in 1L KRAS/NRAS+ mCRC under the cited DCF framework, with value heavily dependent on a single clinical program and uncertain market penetration. The May 27, 2026 notice that Nerviano Medical Sciences is terminating the license agreement adds major legal and operational risk, including allegations of breach, potential loss of development control, and threats to ongoing trial oversight. Combined with the stated risks of poor CRDF-004 data, delays into pivotal studies, approval failure, and near- to medium-term dilution risk, the company’s $848M estimated firm value appears fragile.